Retatrutide News and Updates (October 2026)

The latest retatrutide news is the first head-to-head result: on October 28, 2026, Lilly said retatrutide lowered blood sugar more than Ozempic 2 mg and more than doubled its weight loss in TRANSCEND-T2D-2, the sixth Phase 3 trial with positive results. Earlier in October the FDA decided retatrutide is a drug, not a biological product, and NEJM published its sleep apnea results. No approved version exists yet, and Lilly last said, on September 29, that it plans to submit retatrutide to the FDA in the first quarter of 2027.

This page is a dated log, last checked October 31, 2026. An item counts as news when Lilly, a journal, a regulator or a court puts something on the record, and we link to that primary source. When a news outlet finds something new, we say what it could and couldn't verify.

Every retatrutide news event, newest first

Each event below has its own page with the numbers, the primary source and the date we last checked it against that source. New events go at the top, and the same list is available as an RSS feed.

1. October 28, 2026Retatrutide Beats Ozempic 2 mg in TRANSCEND-T2D-2 (October 28, 2026)TRANSCEND-T2D-2 results, Oct 28, 2026: retatrutide cut A1C 2.2 points vs 1.8 on Ozempic 2 mg and weight 20.9% vs 9.4%. The numbers, the caveats, what's next.
2. October 21, 2026NEJM Publishes the Retatrutide Sleep Apnea Trials (October 21, 2026)Retatrutide sleep apnea results in NEJM, Oct 21, 2026: apnea events fell 34.3 an hour on 9 mg vs 9.9 on placebo in TRIUMPH-1-OSA. Both trials by dose.
3. October 2, 2026FDA Decides Retatrutide Is a Drug, Not a Biologic (October 2, 2026)The retatrutide FDA decision of Oct 2, 2026: a drug, not a biologic, so a filing goes under section 505. What the letter says, the court case, what's next.
4. September 29, 2026TRIUMPH-1 Published in NEJM as Lilly Restates Its 2027 Filing Plan (September 29, 2026)The TRIUMPH-1 NEJM paper, Sep 29, 2026: 25.0% weight loss on 12 mg vs 3.9% on placebo at 80 weeks, the estimand behind it, and Lilly's Q1 2027 filing plan.
5. September 29, 2026TRIUMPH-2 Published in The Lancet (September 29, 2026)The TRIUMPH-2 Lancet paper, Sep 29, 2026: 18.8% weight loss on 12 mg vs 5.1% on placebo in people with type 2 diabetes. Side effects, deaths, A1C targets.
6. September 14, 2026TGA Finds Semaglutide and No Retatrutide in a Vial Sold as Retatrutide (September 14, 2026)TGA retatrutide alert, Sep 14, 2026: a vial sold as retatrutide held none, just semaglutide at about 8 times the approved level. What happened, what to do.
7. August 12, 2026Lilly Files 6 Lawsuits Against Retatrutide Sellers (August 12, 2026)Retatrutide lawsuit news, Aug 12, 2026: Lilly sued 6 US sellers, referred 200+ to regulators and flagged 14,000+ listings. What's verified and what isn't.
8. July 23, 2026TRIUMPH-2 and TRIUMPH-3 Results: Two More Phase 3 Wins (July 23, 2026)TRIUMPH-2 and TRIUMPH-3 results, Jul 23, 2026: 20.8% weight loss with type 2 diabetes and 22.6% with heart disease on 12 mg, plus the heart event counts.
9. June 6, 2026Retatrutide at ADA 2026: TRIUMPH-1 Details and the TRANSCEND-T2D-1 Paper (June 6, 2026)Retatrutide at ADA 2026, Jun 6: TRIUMPH-1 knee pain and sleep apnea results, and TRANSCEND-T2D-1 published in The Lancet. What was new and what changed later.
10. May 21, 2026TRIUMPH-1 Results: 28.3% Average Weight Loss at 80 Weeks (May 21, 2026)TRIUMPH-1 results, May 21, 2026: retatrutide 12 mg gave 28.3% average weight loss at 80 weeks, or 25.0% counting everyone. Doses, side effects and what's next.
11. March 19, 2026TRANSCEND-T2D-1 Results: The First Retatrutide Diabetes Readout (March 19, 2026)TRANSCEND-T2D-1 results, Mar 19, 2026: retatrutide cut A1C by up to 2.0 points and weight by up to 16.8% in 40 weeks in type 2 diabetes. Doses and side effects.
12. December 11, 2025TRIUMPH-4 Results: The First Retatrutide Phase 3 Win (December 11, 2025)TRIUMPH-4 results, Dec 11, 2025: retatrutide's first Phase 3 win, with 28.7% weight loss on 12 mg and knee pain down about three-quarters in 68 weeks.

Retatrutide news from October 2026

The head-to-head result comes first, then the rest of the month in date order.

Retatrutide vs Ozempic, reported October 28

TRANSCEND-T2D-2 randomized 1,298 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg once a week for 80 weeks. It was open label, so everyone knew which drug they were on. From a starting A1C of 8.3%, both retatrutide doses brought it down 2.2 points against 1.8 on Ozempic. Weight fell 19.5% on 9 mg and 20.9% on 12 mg against 9.4% on Ozempic, from an average of 102.4 kg (225.8 lb).

Every number in Lilly's release uses the efficacy estimand (as if everyone had stayed on their assigned drug). The 12 mg comparisons were controlled for false positives; the 9 mg advantage on A1C was nominal only, a weaker finding. Side effects ran close to Ozempic's, with nausea at 21.2% and 23.8% on retatrutide against 21.3%, but more people quit retatrutide because of them: 4.8% on 9 mg and 7.9% on 12 mg against 2.7%. Lilly says full results will come at a future medical meeting and in a journal, and about 650 people are staying on retatrutide for 24 more weeks in an extension. The October 28 news page has the full side effect table.

Our read: the A1C gap is 0.4 points, which matters but is modest. The weight gap, about 21% against 9%, is the bigger news for anyone on Ozempic now, and the retatrutide vs Ozempic page goes through it dose by dose.

The rest of October, in date order

October 2. The FDA finished the review a federal court had sent back to it and again found that retatrutide is not a biological product. Its letter says: "Accordingly, an application for retatrutide would need to be submitted under section 505 of the Federal Food, Drug, and Cosmetic Act." That's the new drug application route, not the biologics license application Lilly has said it plans to file. The court case section below has the background, and the October 2 news page has the full timeline.

October 7. BMJ Case Reports described a woman in her mid-20s with 5 days of nausea and vomiting that wouldn't stop, after 4 weekly injections of an unverified product said to contain retatrutide, given by a non-medical "life coach." She recovered within a week. It's one case, and nobody knows what was in the vial.

October 8. Both sides filed the extra briefs the Seventh Circuit had asked for on whether it can hear Lilly's appeal.

October 13. CBS News reported that the FDA's adverse event reporting system (FAERS) had received 2 reports of deaths in people who took products sold as retatrutide, one in July and one in September. The FDA wouldn't say whether it had checked them, and CBS couldn't verify them. Reports like these flag possible problems for the FDA to look into, and on their own they don't show that a product caused a death. Lilly told CBS the reports make clear both people were taking black-market retatrutide.

October 14. JAMA Network Open published a study of 148,640 Reddit posts and comments about retatrutide. Among the 7,823 users analyzed, the most common self-reported effects were increased appetite (17.1%), fatigue (15.2%), increased energy (12.4%) and nausea (11.6%). Those are self-reports about products that aren't Lilly's, sorted by an AI classifier, not trial data.

October 21. NEJM published the sleep apnea substudies of TRIUMPH-1 and TRIUMPH-2. In the 243 people without diabetes, apnea events fell by 34.3 per hour on 9 mg and 31.7 on 12 mg, against 9.9 on placebo, from a starting average of 58.6 an hour. In the 448 people with type 2 diabetes, the drops were 24.7 and 25.4 against 10.3. Both use the paper's hybrid-treatment estimand, and in the first group the lower dose did a little better. The October 21 news page has every arm.

Also in October, Lilly updated its retatrutide FAQ. It now says: "To date, Lilly has disclosed retatrutide Phase 3 data from six clinical trials." On October 29 Lilly's third-quarter results filing with the SEC listed the Ozempic head-to-head as positive and said nothing new about filing timing.

Retatrutide news from September 2026

September was the month the papers started arriving. On September 29, NEJM published TRIUMPH-1 and The Lancet published TRIUMPH-2, the first full papers for any TRIUMPH trial. NEJM leads with the everyone-randomized result for TRIUMPH-1: 25.0% weight loss on 12 mg against 3.9% on placebo at 80 weeks. The Lancet's equivalent figure for TRIUMPH-2, in people with type 2 diabetes, is 18.8% against 5.1%. Each paper has its own page: TRIUMPH-1 in NEJM and TRIUMPH-2 in The Lancet.

Lilly presented TRIUMPH-2 in detail at the EASD diabetes meeting in Milan on September 30, after a September 15 release announcing the session. Its September 29 release added that at 80 weeks 79.0% of people on 12 mg reached an A1C of 6.5% or below, against 26.3% on placebo, and 52.0% lost 20% or more of their body weight, against 1.5% (efficacy estimand).

On September 14, Australia's Therapeutic Goods Administration (TGA) reported a person who had uncontrollable vomiting and a torn esophagus and needed hospital care after using a product sold as retatrutide. The TGA tested the vial and found no retatrutide, just undeclared semaglutide at about 8 times the level in approved semaglutide products (the TGA test). Ten days later, on September 24, the Seventh Circuit ordered both sides to file briefs on its jurisdiction by October 8.

Six Phase 3 results in under 11 months

Lilly announced the first Phase 3 result on December 11, 2025 and the sixth on October 28, 2026. Every trial met its main goal. The table lists them in the order they became news, with the top dose's average weight loss as Lilly reported it (efficacy estimand) and whether a journal has published the full results.

Sources: Lilly topline releases for each trial; journal status from a Europe PMC title search through October 31, 2026. Numbers of people are those randomized, as Lilly reports them; they add up to 7,720 (our sum, since Lilly gives no combined total).

Line them up and the three lowest top-dose averages all come from people with type 2 diabetes: 16.8%, 20.8% and 20.9%. TRIUMPH-3 also counted heart events, but too few to settle anything. The 5-part count favored retatrutide (44 against 52 events, hazard ratio 0.82, 95% confidence interval 0.55 to 1.22, which crosses 1), and the 3-part count went the other way (27 against 23). TRIUMPH-Outcomes, with about 10,000 people, is built to answer that, and ClinicalTrials.gov doesn't expect its main results until February 2029.

The retatrutide clinical trials guide has the doses and side effects for each trial.

Approval, the 2027 filing and expanded access

Retatrutide is still investigational. Lilly's October FAQ puts it plainly: "Retatrutide is an investigational medicine that is not on the market." Lilly last said, on September 29, 2026, that it plans to submit retatrutide to the FDA in the first quarter of 2027 as a Biologics License Application (BLA). On October 2, 2026, the FDA decided that retatrutide is a drug, not a biological product, so an application would need to be filed under section 505 of the Federal Food, Drug, and Cosmetic Act. Lilly's appeal on that question is pending in the Seventh Circuit, and we found no ruling as of October 31, 2026.

Lilly's August 5 earnings filing with the SEC said the clinical data package is complete to support registrations for obesity, obstructive sleep apnea and knee osteoarthritis pain. Neither the October 28 release nor the October 29 earnings filing restates a filing date.

There's no launch date and no price. Lilly's FAQ says launch "will depend on the completion of these trials and the regulatory approval process," and that it plans to make sure retatrutide is "priced to reflect the overall value to the healthcare system." The one route before approval is the expanded access program Lilly posted on ClinicalTrials.gov on June 5, 2026, and it's narrow: adults with a BMI of 35 or more despite the highest available dose of weight-management treatment, 2 or more serious obesity-related complications, and no way into a trial. The treating doctor contacts Lilly, not the patient. For most people a trial is the more realistic route, and retatrutide near me covers how to find a site.

The FDA approval page covers what the review involves, and the retatrutide release date page works through when a 2027 filing could reach pharmacies.

The court case over whether retatrutide is a biologic

Lilly sued the FDA on September 3, 2024, challenging the agency's March 2024 decision that retatrutide is a drug, not a biological product. In an amended order filed October 3, 2025, a federal judge in Indiana upheld the FDA on what counts as a protein but threw out its finding that retatrutide isn't "analogous" to a protein, and sent that part back to the agency. Lilly appealed to the Seventh Circuit on February 12, 2026.

While the appeal was pending, the FDA answered the question the court sent back. Its October 2, 2026 letter says retatrutide "is neither a 'protein' nor an 'analogous product' to a 'protein' and is therefore not a biological product." On October 8, the letter was filed with the appeals court along with the jurisdiction briefs it had asked for. The Justice Department argued that "Lilly cannot appeal a district court's order remanding to an agency." Lilly argued the FDA's new decision confirms "that this appeal is the only proceeding that can address the issues presented here." We found no later entry on the docket as of October 31.

The case decides which application route retatrutide takes. The FDA will judge whether retatrutide works and is safe on the trial data either way.

The crackdown on retatrutide sold online

Alongside the trial results, 2026 brought a steady run of enforcement news about vials and pens sold without any approval. This is the dated record from the regulators and Lilly.

Lilly's 2026 releases say retatrutide is "legally available only to participants in Lilly's clinical trials" and "cannot be legally sold or marketed for human use." Its October 28 release goes further: "Anyone purporting to sell retatrutide to consumers is breaking the law." The FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, says: "Retatrutide and cagrilintide cannot be used in compounding under federal law." So anything labeled retatrutide that you can buy isn't Lilly's product, and Lilly's October FAQ warns it can hold the wrong ingredient, the wrong amount or contaminants.

If you've been reading about retatrutide for sale, the TGA result is the one to remember: the vial was sold as retatrutide, and the lab found none in it. Whether it's legal to buy or own a vial where you live is covered on the is retatrutide legal page, and the is retatrutide safe page separates the trial safety data from what's known about these products.

What CBS News reported about retatrutide

CBS News has come back to retatrutide again and again this year. On June 8, 2026, it reported dozens of clinics and med spas openly advertising retatrutide, and some doctors prescribing it, even though no approved version exists. On July 2, its reporters bought a vial at a Brooklyn convenience store with no prescription, and the testing lab named on the seller's purity reports told CBS it hadn't issued them. It covered Lilly's lawsuits on August 12, and on September 16 it reported on websites selling retatrutide under a certification seal that made them look trustworthy.

The October 13 report was about deaths. CBS got the 2 death reports through a records request. One, from a health care professional, described a woman who went into cardiac arrest after taking retatrutide from what the report called an unreliable source. Lilly told CBS the reports make clear that both people were taking black-market retatrutide. CBS also reported, citing America's Poison Centers, that retatrutide exposure reports rose from 249 in the first 3 months of 2026 to 862 in the 3 months ending in September. We couldn't find those counts published by the poison centers themselves.

These are news reports, and the death reports are unverified. The Brooklyn story shows why a purity report on a seller's website proves little until the lab named on it confirms it.

What's coming next

This is what's scheduled, as of October 31, 2026. Trial dates are ClinicalTrials.gov estimates of when each trial finishes collecting its main results, and Lilly hasn't said when it will announce any of them.

• October 2026 (estimated): TRANSCEND-T2D-3, about 320 adults with type 2 diabetes, moderate or severe kidney impairment and basal insulin, against placebo. No result as of October 31.
• November 2026 (estimated): TRIUMPH-5, about 800 adults with obesity, retatrutide head to head with tirzepatide over 80 weeks. Lilly's past toplines came 27 to 98 days after primary completion; TRANSCEND-T2D-2 took 62. That points to about late November 2026 to early March 2027 (our arithmetic).
• No date: a Seventh Circuit ruling on whether it can hear Lilly's appeal.
• First quarter of 2027: Lilly's planned US filing, on its September 29 statement.
• February 2027 (estimated): the TRANSCEND-T2D-2 extension finishes.
• Later: TRIUMPH-8 around July 2027, TRIUMPH-7 (low back pain) around September 2027, TRIUMPH-6 (keeping weight off) around April 2028, TRIUMPH-Outcomes around February 2029, and SYNERGY-Outcomes, a fatty liver trial still recruiting, around August 2030.

Our read: TRIUMPH-5 is the result to wait for if you're on tirzepatide now. The Ozempic trial is one head-to-head, in type 2 diabetes, and every other weight number on this page compares retatrutide with placebo, and the retatrutide vs tirzepatide page lines up what can and can't be compared until then.

How to read the next retatrutide update

A few checks sort real news from recycled headlines.

1. Find the primary source. A real result comes from a Lilly release, a journal paper, a regulator or a court filing. If an article can't point to one, it's probably repeating an old number.
2. Check which estimand you're reading. In TRIUMPH-1, 12 mg averaged 28.3% as if everyone stayed on treatment, and 25.0% counting everyone who started, which is the figure NEJM leads with. Both are true, and Lilly's releases lead with the bigger one.
3. Watch for "up to." Lilly's June release gave TRIUMPH-1's sleep apnea result as "up to 36.1 events per hour," using the efficacy estimand. The NEJM paper's main analysis, with a different estimand, gives 34.3 on 9 mg and 31.7 on 12 mg against 9.9 on placebo. An "up to" figure picks the best arm and leaves out placebo.
4. Treat "approved," "now available" or "GLP-3" as red flags. No approved version exists, and Lilly calls "GLP-3" a scientifically inaccurate label. A DailyMed listing titled "RETATRUTIDE PEN injection, solution" comes from a Guangzhou e-commerce company, is marked "Export only" and has no application number. It isn't an FDA approval.
5. Separate progress posts from news. Reddit progress posts, the "retatrutide update" threads, report one person's scale, and nothing confirms what was in that person's vial. Our retatrutide Reddit page covers what those threads can and can't tell you.

When TRIUMPH-5 reports, the number to look for is the difference in percent body weight lost against tirzepatide at week 80, the trial's main goal, along with which estimand Lilly used.